Remilk, an Israeli producer of plant-based dairy products through microbial fermentation, announced receiving regulatory approval from the Singapore Food Authority (SFA), as well as a “no questions” letter from the FDA.
The approval from the SFA will enable the sale of Remilk products in Singapore. While the company declared self-affirmed GRAS status in 2022 according to FDA protocols, the “no questions” letter from the FDA further establishes Remilk’s animal-free whey proteins as safe for consumption (following consensus from a panel of experts).
Analyst QuickTake: Both of these approvals are major milestones for Remilk, given that Singapore and the US are at the forefront of the alternative protein industry. Apart from the ability to sell its products, the company will be able to attract more investments and focus on R&D as regulatory approval—especially from the FDA—is seen as a variable that reduces the risk factor of a brand.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.